antagonist dy268 Search Results


antagonist dy268  (TargetMol)
93
TargetMol antagonist dy268
Antagonist Dy268, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antagonist dy268/product/TargetMol
Average 93 stars, based on 1 article reviews
antagonist dy268 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
fxr antagonist dy268  (MedChemExpress)
94
MedChemExpress fxr antagonist dy268
Fxr Antagonist Dy268, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fxr antagonist dy268/product/MedChemExpress
Average 94 stars, based on 1 article reviews
fxr antagonist dy268 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
dy268 (fxr antagonist)  (Axon Medchem LLC)
90
Axon Medchem LLC dy268 (fxr antagonist)
Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist <t>DY268</t> (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
Dy268 (Fxr Antagonist), supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dy268 (fxr antagonist)/product/Axon Medchem LLC
Average 90 stars, based on 1 article reviews
dy268 (fxr antagonist) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
dy268  (Tocris)
94
Tocris dy268
Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist <t>DY268</t> (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
Dy268, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dy268/product/Tocris
Average 94 stars, based on 1 article reviews
dy268 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

Image Search Results


Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

Journal: The Journal of Biological Chemistry

Article Title: Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway

doi: 10.1016/j.jbc.2022.102056

Figure Lengend Snippet: Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

Article Snippet: DY268 (FXR antagonist) was from Axon Medchem.

Techniques: Gene Expression, Control